Blog: VIRIOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On November 16, 2022, Virios Therapeutics, Inc. (the “Company”) will be posting
a presentation to its website that may be used by the Company from time to time
with investors, analysts, collaborators, vendors or other third parties. A copy
of the presentation is furnished as Exhibit 99.1.

The information in this Item 7.01, including the attached exhibit, is furnished
solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, or otherwise subject to the liabilities of that section. Further, the
information in this Item 7.01, including the exhibit, shall not be deemed to be
incorporated by reference into the filings of the registrant under the
Securities Act of 1933.

Cautionary Statement Regarding Forward-Looking Information

This current report on Form 8-K contains “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are
subject to substantial risks and uncertainties. All statements other than those
of historical fact in this presentation and accompanying oral commentary are
forward-looking statements. Forward-looking statements may be identified by
terminology such as “believe,” “anticipate,” “plan,” “may,” “intend,” “will,”
“should,” “expect,” “estimate,” “potential”, “outlook”, “forecast” and
“continue” and similar expressions, including the negative of these words, but
not all forward-looking statements contain these words. Forward-looking
statements include, but are not limited to, statements regarding the Company’s
expectations regarding our future financial or business performance, plans,
prospects, trends or strategies, objectives of management, competition and other
financial and business matters; the potential, safety, efficacy, and regulatory
and clinical progress of our current and prospective product candidates, planned
clinical trials and preclinical activities, and projected research and
development costs; the estimated size of the market for our product candidates;
and the timing and success of our development and commercialization of our
anticipated product candidates and the market acceptance thereof.
Forward-looking statements are based on our current expectations and are subject
to inherent uncertainties, risks and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These statements are neither
promises nor guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements, including,
but not limited to, the following: risks generally related to the completion,
timing and results of current and future research or clinical studies relating
to our product candidates; the ongoing effects of COVID-19 has adversely
impacted and may continue to adversely impact our business, including our
preclinical studies and clinical trials; our limited operating history, which
may make it difficult to evaluate our current business and predict our future
success and viability; we have and expect to continue to incur significant
losses; our need for additional funding, which may not be available; our
substantial dependence on the success of our lead product candidates; failure to
identify additional product candidates and develop or commercialize marketable
products; the early stage of our development efforts; potential unforeseen
events during clinical trials could cause delays or other adverse consequences;
risks relating to the regulatory approval process or ongoing regulatory
obligations; our product candidates may cause serious adverse side effects; our
reliance on third parties; effects of significant competition; the possibility
of system failures or security breaches; risks relating to intellectual
property; our ability to attract, retain and motivate qualified personnel; and
significant costs as a result of operating as a public company. These and other
risks and uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended December 31, 2021
filed with the Securities and Exchange Commission (“SEC”) and elsewhere in our
filings and reports with the SEC. While we may elect to update these
forward-looking statements at some point in the future, we assume no obligation
to update or revise any forward-looking statements except to the extent required
by applicable law. Although we believe the expectations reflected in such
forward-looking statements are reasonable, we can give no assurance that such
expectations will prove to be correct. Accordingly, readers are cautioned not to
place undue reliance on these forward-looking statements. No representations or
warranties (expressed or implied) are made about the accuracy of any such
forward-looking statements.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number                               Description
99.1                Presentation dated November 2022 (furnished herewith).
104               Cover Page Interactive Data File (formatted in Inline XBRL and
                  contained in Exhibit 101)


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s